Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial.
Felix EcksteinJeffrey L KrainesAida AydemirWolfgang WirthSusanne MaschekMarc C HochbergPublished in: Annals of the rheumatic diseases (2020)
NCT01919164.